4588 — Oncolys Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- ¥55bn
- ¥54bn
- ¥31m
Annual cashflow statement for Oncolys Biopharma, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1,612 | -1,146 | -1,936 | -1,681 | -2,054 |
| Depreciation | |||||
| Non-Cash Items | 351 | 13 | 22.2 | 33.8 | 79.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -488 | -585 | 574 | -374 | 33 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1,742 | -1,717 | -1,337 | -2,020 | -1,941 |
| Capital Expenditures | -1.44 | -1.36 | -5.69 | -3.52 | -3.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.495 | 21.5 | 0.294 | -1.19 | -4.57 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.942 | 20.1 | -5.39 | -4.71 | -7.58 |
| Financing Cash Flow Items | 30.8 | -0.031 | 18.1 | -5 | 32.7 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3,091 | -114 | 1,143 | 2,879 | 3,222 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,387 | -1,743 | -178 | 878 | 1,264 |